Thiogenesis Therapeutics, Corp.

TSXV:TTI Stock Report

Market Cap: CA$27.3m

Thiogenesis Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Patrice Rioux

Chief executive officer

CA$261.7k

Total compensation

CEO salary percentage100.0%
CEO tenure2.8yrs
CEO ownership14.9%
Management average tenureno data
Board average tenure2.8yrs

Recent management updates

Recent updates

We're Keeping An Eye On Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate

Nov 20
We're Keeping An Eye On Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate

We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully

Jul 17
We Think Thiogenesis Therapeutics (CVE:TTI) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation

Aug 25
Here's Why We're Not Too Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Situation

We're Not Very Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate

May 01
We're Not Very Worried About Thiogenesis Therapeutics' (CVE:TTI) Cash Burn Rate

CEO Compensation Analysis

How has Patrice Rioux's remuneration changed compared to Thiogenesis Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$4m

Jun 30 2024n/an/a

-CA$4m

Mar 31 2024n/an/a

-CA$5m

Dec 31 2023CA$262kCA$262k

-CA$5m

Sep 30 2023n/an/a

-CA$3m

Jun 30 2023n/an/a

-CA$3m

Mar 31 2023n/an/a

-CA$3m

Dec 31 2022CA$139kCA$139k

-CA$4m

Compensation vs Market: Patrice's total compensation ($USD182.10K) is about average for companies of similar size in the Canadian market ($USD164.07K).

Compensation vs Earnings: Patrice's compensation has increased whilst the company is unprofitable.

CEO

Patrice Rioux (73 yo)

2.8yrs

Tenure

CA$261,683

Compensation

Dr. Patrice P. Rioux, M. D., Ph. D, is a Co-founder of Thiogenesis Therapeutics, Corp. and its Chief Executive Officer and Director since March 31, 2022. He serves as Co-President, Director and Chief Execu...

Board Members

NamePositionTenureCompensationOwnership
Patrice Rioux
Co-Founder2.8yrsCA$261.68k14.88%
CA$ 4.1m
Brook G. Riggins
CFO, Secretary & Director6.6yrsCA$221.78k2.31%
CA$ 630.0k
Christopher Starr
Independent Chairman2.8yrsCA$32.39kno data
David Housman
Member of Scientific Advisory Board2.3yrsno datano data
Kim Tsuchimoto
Independent Director2.8yrsCA$32.39kno data
Miriam Vos
Member of Scientific Advisory Board2.3yrsno datano data
W. Mullally
Independent Director6.6yrsCA$32.21k1.92%
CA$ 525.0k
Gregory Enns
Member of Scientific Advisory Board2.3yrsno datano data

2.8yrs

Average Tenure

66.5yo

Average Age

Experienced Board: TTI's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 06:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Thiogenesis Therapeutics, Corp. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bob PoolerValuationLAB AG